H1

Sanofi received FDA approval for #Qfitlia, a small interfering RNA (siRNA) drug that distinguishes itself as the only one that can treat all types of #hemophilia. This medication is approved not only for patients with hemophilia A or B, but can also be used regardless of inhibitor status. Qtiflia suppresses a protein that inhibits blood clotting and helps prevent bleeding episodes by imitating a natural process that regulates gene expression. Learn more: https://hubs.la/Q03fy1000

When Taro Health was first starting up, they needed to find a technology partner to build a provider data infrastructure that could power their “Find Care” tool to connect their members with relevant, in-network providers. See how H1 processed and enriched their raw data and delivered it via API to Taro’s proprietary provider search platform. Get the case study: https://lnkd.in/ecRPtaRk

Patient representation in clinical trials is more than just a regulatory requirement—it’s a critical component of equitable healthcare. Trial participants must reflect real-world patient populations in order to deliver more effective treatments for everyone. In a recent discussion, Dija Atta, Head of Regional Clinical Operations, and Stacy Eckstein, Manager of Global Trial Informatics, shared how Incyte is taking meaningful steps toward more inclusive research. Read the blog: https://hubs.la/Q03fBRcR0

Are you prepared for new global standards in clinical trial diversity? Across North America and Europe, healthcare regulatory bodies are releasing new and updated guidance and requirements for clinical trial diversity planning. In partnership with FirstWord Pharma, we’ve released an industry poll & analysis to help you keep up with the latest developments, see how other life sciences companies are preparing, and discover tools that can support your goals. Download the report: https://hubs.ly/Q03f9CnG0

Provider information is constantly changing, making accurate data a moving and expensive target. Did you know that only 38% trust their health plan to find a provider that's right for them? Download The State of Provider Data Accuracy Report to see the current state of provider data accuracy and explore better ways to maintain accurate provider information. Get it now: https://hubs.la/Q03dsQRx0

Today on #NationalDoctorsDay we recognize and express gratitude to every physician in the medical field! Doctors fill so many critical roles, from treating patients to assisting with the development of new medicines, and so much more. At H1, we truly appreciate the work that healthcare professionals do and we work closely with organizations across the industry to connect them with the right doctors. One of the ways we do this is by connecting doctors with NGOs to open up opportunities to join global medical missions. Learn more about H1 Connect and how HCPs can get involved: https://hubs.la/Q03dyDcN0 You can also learn about the key insights that our comprehensive HCP data offers to pharma, CROs, health plans, digital health companies, and more: https://hubs.la/Q03dyP5W0

Alnylam Pharmaceuticals has received FDA approval for Amvuttra, an RNA interference drug, to be used as a treatment for cardiomyopathy of wild-type or hereditary AATR-CM in adults. The drug met all 10 of its primary and secondary endpoints in a phase 3 trial, reducing the risk of all-cause mortality and recurrent cardiovascular events by 28% versus placebo. With this latest approval, Amvuttra became the first medication approved in the U.S. to treat both ATTR-CM and polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN). https://hubs.la/Q03dpdMj0

Thank you to Medical Affairs Professional Society (MAPS) for amplifying this story! Our partnership with J&J is a great example of how the right data insights can have transformative results.

Unreliable site and investigator data can disrupt your clinical operations. H1 can help your teams spend their time uncovering insights instead of sifting through data. H1's Global Clinical Identifier (GCI) offers a global reference dataset across all entities related to clinical trials, including investigators, institutions and sites. GCI helps you: ✔️ Avoid underperforming site investments ✔️ Eliminate expenses from inaccurate address data ✔️ Clarify complex relationships between entities GCI is the "single source of truth" for high-quality global trial data. Download the product overview to learn more: https://hubs.la/Q03dtbWS0

The last day of #MAPS is already here. Thank you to everyone who's been by our booth this week already. We've had some amazing conversations! There's still time to stop by Booth 207 if you'd like to see how our solutions can support your Medical Affairs team. See you soon! #MAPS #MAPSAmericas #medicalaffairs